| アブストラクト | Randomized controlled trials (RCTs) have shown an antidepressant effect of glabellar botulinum toxin (BoNT) injections. In the FDA Adverse Event Reporting System (FAERS) database, BoNT injection is associated with reduced incidence rates of depression across various non-psychiatric indications, which confirms the previous findings independently of specific expectations to an antidepressant effect of BoNT. The rationale of using BoNT to treat depression is to interrupt proprioceptive body feedback that may reinforce negative emotions. Negative emotions also occur in other mental disorders, suggesting a transdiagnostic therapeutic potential of BoNT in psychiatry. Here we report an analysis of the FAERS database, in which we found that, compared to alternative treatments, BoNT injections were associated with lower incidence of anxiety symptoms and related disorders. Among seven indications/injection sites, we found this protective effect of BoNT in cosmetic use/facial muscles, migraine/facial and head muscles, spasms and spasticity/upper and lower limbs, torticollis and neck pain/neck muscles, and sialorrhea/parotid and submandibular glands (reporting odds ratios 0.79-0.27). These findings are encouraging for possible future RCTs on the use of BoNT as a treatment for anxiety and related disorders. |
|---|
| 組織名 | Asklepios Clinic North - Ochsenzoll, Asklepios Campus Hamburg, Medical Faculty,;Semmelweis University, Hamburg, Germany. m.wollmer@asklepios.com.;Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California;San Diego, La Jolla, CA, USA.;Oak Ridge Institute of Science and Education Fellowship at Office of Clinical;Pharmacology, United States Food and Drug Administration, Oak Ridge, USA.;Hannover Medical School, Division of Clinical Psychology and Sexual Medicine,;Department of Psychiatry, Social Psychiatry and Psychotherapy, Hannover, Germany.;San Diego, La Jolla, CA, USA. rabagyan@health.ucsd.edu. |
|---|
